Holen Sie sich die Stockscreener-App
2.96
3.27%
-0.10
Schlusskurs vom Vortag:
$3.06
Offen:
$3.11
24-Stunden-Volumen:
834.96K
Relative Volume:
0.59
Marktkapitalisierung:
$307.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-166.01M
KGV:
-1.4246
EPS:
-2.0778
Netto-Cashflow:
$-131.32M
1W Leistung:
-3.74%
1M Leistung:
-23.51%
6M Leistung:
-38.20%
1J Leistung:
-30.84%
1-Tages-Spanne:
$2.92
$3.11
1-Wochen-Bereich:
$2.92
$3.2308
52-Wochen-Spanne:
$2.715
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Firmenname
Larimar Therapeutics Inc
Sektor
Branche
Telefon
844-511-9056
Adresse
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
2.96 | 319.44M | 0 | -166.01M | -131.32M | -2.0778 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-29 | Eingeleitet | Truist | Buy |
| 2024-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-03 | Eingeleitet | Wedbush | Outperform |
| 2024-10-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-03 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-19 | Eingeleitet | Guggenheim | Buy |
| 2022-02-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-02-01 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Larimar Therapeutics Inc Aktie (LRMR) Neueste Nachrichten
John Harlow Joins Larimar Therapeutics as President and Chief Operating Officer - BioBuzz
Larimar Therapeutics appoints John B. Harlow, Jr. as president and COO - Investing.com
Larimar Therapeutics names John Harlow president and COO - Investing.com
Form 8K Larimar Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Larimar Therapeutics names John Harlow president and COO By Investing.com - Investing.com South Africa
Larimar Therapeutics Names John Harlow COO - marketscreener.com
Larimar appoints John B. Harlow, Jr. as President and COO - TradingView
Larimar Therapeutics Strengthens Executive Leadership with - GlobeNewswire
Larimar Therapeutics, Inc. Announces Appointment of John Harlow as President and Chief Operating Officer, Effective September 29, 2026 - marketscreener.com
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - Stocktwits
LRMR News | LARIMAR THERAPEUTICS INC (NASDAQ:LRMR) - ChartMill
Two cell therapies head toward 2026 milestones. One targets type 1 diabetes. - stocktitan.net
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns - Stocktwits
Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play - TipRanks
Price to earnings forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Larimar (LRMR) Earnings Snapshot: EPS Prints Above Forecast at the Close; Share Move: The Market Price Advances 2.72%Revenue Miss Report - careplusvn.com
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits
LRMR Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.30 Signals Continued Clinical ProgressPost-Earnings Drift - dars.gov.et
Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat
Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR - MarketBeat
LRMR Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock UptickAnalyst Drop Coverage - dars.gov.et
Larimar Advances FDA Filing as Drug Costs Push Loss Higher - MyChesCo
Renaissance Technologies LLC Has $3.33 Million Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat
LRMR Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Cycle Outlook - dars.gov.et
Larimar Therapeutics (LRMR) to Announce Earnings on Thursday - marketbeat.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp - The Globe and Mail
William Blair Maintains Larimar Therapeutics(LRMR.US) With Buy Rating - Moomoo
LRMR Maintained by Wedbush -- Price Target Lowered to $11.00 - GuruFocus
Wedbush Cuts Larimar Therapeutics (NASDAQ:LRMR) Price Target to $11.00 - MarketBeat
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Larimar Therapeutics (LRMR) Advances Nomlabofusp Submission Amid Mixed Financial Signals - GuruFocus
Larimar Therapeutics 2Q 2026: Net loss $32.8M, Diluted EPS $(0.30) — 10-Q Summary - TradingView
Larimar Therapeutics Reports Positive Longer-Term Nomlabofusp Data and Progress Toward Rolling BLA Submission for Friedreich’s Ataxia - Quiver Quantitative
Larimar: Q2 Earnings Snapshot - marketscreener.com
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update - Yahoo Finance
Larimar Therapeutics (LRMR) Gains 3.27% as Biotech Stock Approaches Key $4.32 ResistanceDemand Zone - dars.gov.et
LRMR Q1 2026 Earnings: Loss Narrows to -$0.31 Per Share, Beating Estimates by 43.19%Capex Guidance - dars.gov.et
LRMR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Larimar Therapeutics Inc (LRMR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Larimar Therapeutics Inc (LRMR) Institutional Confidence - TradingKey
LRMR|Larimar Therapeutics Inc|Price:3.820|Chg%:-0.180 - TradingKey
Larimar Therapeutics Inc (LRMR) Cash Flow - TradingKey
Enterprise value to EBITDA forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
TradingKey - TradingKey
Larimar Therapeutics Market Sentiment - Benzinga España
Larimar Therapeutics, Inc. Revenue Breakdown – NASDAQ:LRMR - tradingview.com
What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter - Kavout | AI
Finanzdaten der Larimar Therapeutics Inc-Aktie (LRMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Larimar Therapeutics Inc-Aktie (LRMR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Flynn James E | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000,000 |
25,000,000 |
10,622,957 |
| Hamilton Thomas Edward | Director |
Feb 27 '26 |
Buy |
5.00 |
100,000 |
500,000 |
664,798 |
| THOMAS FRANK E | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
7,000 |
| SHERMAN JEFFREY W | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
5,000 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):